WENDY KEITEL to Female
This is a "connection" page, showing publications WENDY KEITEL has written about Female.
Connection Strength
0.569
-
Safety and immunogenicity of three seasonal inactivated influenza vaccines among pregnant women and antibody persistence in their infants. Vaccine. 2020 07 14; 38(33):5355-5363.
Score: 0.028
-
A phase 1 study of the safety, reactogenicity, and immunogenicity of a Schistosoma mansoni vaccine with or without glucopyranosyl lipid A aqueous formulation (GLA-AF) in healthy adults from a non-endemic area. Vaccine. 2019 10 08; 37(43):6500-6509.
Score: 0.026
-
Safety and immunogenicity of unadjuvanted subvirion monovalent inactivated influenza H3N2 variant (H3N2v) vaccine in children and adolescents. Vaccine. 2019 08 23; 37(36):5161-5170.
Score: 0.026
-
Effect of recent seasonal influenza vaccination on serum antibody responses to candidate pandemic influenza A/H5N1 vaccines: A meta-analysis. Vaccine. 2019 09 03; 37(37):5535-5543.
Score: 0.026
-
Safety and immunogenicity of seasonal trivalent inactivated influenza vaccines in pregnant women. Vaccine. 2018 12 18; 36(52):8054-8061.
Score: 0.025
-
Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine. Vaccine. 2016 Jan 20; 34(4):547-554.
Score: 0.020
-
Influenza Vaccination of Patients Receiving Statins: Where Do We Go From Here? J Infect Dis. 2016 Apr 15; 213(8):1211-3.
Score: 0.020
-
Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons =18 Years Old. J Infect Dis. 2015 Aug 15; 212(4):552-61.
Score: 0.019
-
Influenza A(H5N1) vaccines: are we better prepared for the next pandemic? J Infect Dis. 2014 Jan 01; 209(1):1-3.
Score: 0.017
-
Effects of infection and disease with Mycobacterium tuberculosis on serum antibody to glucan and arabinomannan: two surface polysaccharides of this pathogen. BMC Infect Dis. 2013 Jun 19; 13:276.
Score: 0.017
-
Rapid research response to the 2009 A(H1N1)pdm09 influenza pandemic (Revised). BMC Res Notes. 2013 May 03; 6:177.
Score: 0.017
-
Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes. J Infect Dis. 2012 Oct 01; 206(7):1069-77.
Score: 0.016
-
Higher antigen content improves the immune response to 2009 H1N1 influenza vaccine in HIV-infected adults: a randomized clinical trial. J Infect Dis. 2012 Mar 01; 205(5):703-12.
Score: 0.015
-
Safety and immunogenicity of a recombinant nonglycosylated erythrocyte binding antigen 175 Region II malaria vaccine in healthy adults living in an area where malaria is not endemic. Clin Vaccine Immunol. 2010 Oct; 17(10):1552-9.
Score: 0.014
-
A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route. Vaccine. 2010 Apr 09; 28(17):3025-9.
Score: 0.013
-
Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. Vaccine. 2010 Jan 08; 28(3):840-8.
Score: 0.013
-
Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults. Hum Vaccin. 2009 Aug; 5(8):536-44.
Score: 0.013
-
Safety, reactogenicity and immunogenicity of Francisella tularensis live vaccine strain in humans. Vaccine. 2009 Aug 06; 27(36):4905-11.
Score: 0.013
-
Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults. Vaccine. 2009 Nov 05; 27(47):6642-8.
Score: 0.013
-
Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. J Infect Dis. 2008 Nov 01; 198(9):1309-16.
Score: 0.012
-
Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med. 2006 May 22; 166(10):1121-7.
Score: 0.010
-
Postnatal Zika and Dengue Infection and their Effects on Neurodevelopment Among Children Living in Rural Guatemala. Pediatr Infect Dis J. 2025 Apr 01; 44(4):290-298.
Score: 0.009
-
A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults. Clin Infect Dis. 2024 06 14; 78(6):1757-1768.
Score: 0.009
-
Challenges and lessons learned from the rapid operationalization of a prospective cohort to study the natural history and neurodevelopmental outcomes of postnatal Zika virus infection among infants and children in rural Guatemala. PLoS Negl Trop Dis. 2022 11; 16(11):e0010480.
Score: 0.008
-
Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2019. MMWR Recomm Rep. 2019 12 13; 68(4):1-14.
Score: 0.007
-
Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination. Vaccine. 2019 05 01; 37(19):2561-2568.
Score: 0.006
-
Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74?years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine. 2018 01 29; 36(5):606-614.
Score: 0.006
-
Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial. Vaccine. 2017 08 24; 35(36):4730-4737.
Score: 0.006
-
Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period. Vaccine. 1997 Jul; 15(10):1114-22.
Score: 0.006
-
Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial. Vaccine. 2017 03 23; 35(13):1675-1682.
Score: 0.006
-
Increasing doses of purified influenza virus hemagglutinin and subvirion vaccines enhance antibody responses in the elderly. Clin Diagn Lab Immunol. 1996 Sep; 3(5):507-10.
Score: 0.005
-
Severe paroxysmal coughing and pleuritic pain in an adult. Hosp Pract (1995). 1995 Dec 15; 30(12):65-7.
Score: 0.005
-
Persistence of Antibody to Influenza A/H5N1 Vaccine Virus: Impact of AS03 Adjuvant. Clin Vaccine Immunol. 2016 01; 23(1):73-7.
Score: 0.005
-
Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. JAMA. 2015 Jul 21; 314(3):237-46.
Score: 0.005
-
Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-na?ve subjects. Vaccine. 2015 Sep 22; 33(39):5225-34.
Score: 0.005
-
Pertussis in adolescents and adults: time to reimmunize? Semin Respir Infect. 1995 Mar; 10(1):51-7.
Score: 0.005
-
Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine. J Infect Dis. 2015 Aug 15; 212(4):525-30.
Score: 0.005
-
Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations. Vaccine. 2015 Jan 01; 33(1):163-73.
Score: 0.005
-
Evaluation of sex, race, body mass index and pre-vaccination serum progesterone levels and post-vaccination serum anti-anthrax protective immunoglobulin G on injection site adverse events following anthrax vaccine adsorbed (AVA) in the CDC AVA human clinical trial. Vaccine. 2014 Jun 12; 32(28):3548-54.
Score: 0.005
-
Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: a randomized trial. Vaccine. 2014 Feb 12; 32(8):1019-28.
Score: 0.004
-
Assessing agreement of repeated binary measurements with an application to the CDC's anthrax vaccine clinical trial. Int J Biostat. 2013 Jul 27; 9(1).
Score: 0.004
-
Safety of zoster vaccine in elderly adults following documented herpes zoster. J Infect Dis. 2013 Aug 15; 208(4):559-63.
Score: 0.004
-
Prenatal passive transfer of maternal immunity in Asian elephants (Elephas maximus). Vet Immunol Immunopathol. 2013 Jun 15; 153(3-4):308-11.
Score: 0.004
-
The Human Microbiome Project strategy for comprehensive sampling of the human microbiome and why it matters. FASEB J. 2013 Mar; 27(3):1012-22.
Score: 0.004
-
Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines. Vaccine. 2012 Dec 17; 31(1):190-5.
Score: 0.004
-
Health-related quality of life in the CDC Anthrax Vaccine Adsorbed Human Clinical Trial. Vaccine. 2012 Aug 31; 30(40):5875-9.
Score: 0.004
-
Perspectives on human microbiome research ethics. J Empir Res Hum Res Ethics. 2012 Jul; 7(3):1-14.
Score: 0.004
-
Immunogenicity of an inactivated monovalent 2009 H1N1 influenza vaccine in pregnant women. J Infect Dis. 2011 Sep 15; 204(6):854-63.
Score: 0.004
-
Evaluation of age-related differences in the immunogenicity of a G9 H9N2 influenza vaccine. Vaccine. 2011 Oct 19; 29(45):8066-72.
Score: 0.004
-
Safety and immunogenicity of a candidate parvovirus B19 vaccine. Vaccine. 2011 Oct 06; 29(43):7357-63.
Score: 0.004
-
Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. Vaccine. 2009 Aug 13; 27(37):5091-5.
Score: 0.003
-
Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. Arch Intern Med. 2008 Dec 08; 168(22):2405-14.
Score: 0.003
-
Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. JAMA. 2008 Oct 01; 300(13):1532-43.
Score: 0.003
-
Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine. Vaccine. 2008 Jul 29; 26(32):4057-61.
Score: 0.003
-
Response to letter to the editor "Zink TK. Vaccine 2007;25(15):2766-7". Vaccine. 2007 Oct 16; 25(42):7285-7.
Score: 0.003
-
A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults. Vaccine. 2007 Jul 20; 25(29):5367-73.
Score: 0.003
-
Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial. Vaccine. 2006 Aug 14; 24(33-34):5950-9.
Score: 0.003
-
Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med. 2005 Oct 13; 353(15):1555-63.
Score: 0.003
-
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005 Jun 02; 352(22):2271-84.
Score: 0.002
-
Prevalence of antibody to Bordetella pertussis antigens in serum specimens obtained from 1793 adolescents and adults. Clin Infect Dis. 2004 Dec 01; 39(11):1715-8.
Score: 0.002
-
Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study. J Infect Dis. 2004 Aug 01; 190(3):535-44.
Score: 0.002
-
Healthy elderly people lack neutrophil-mediated functional activity to type V group B Streptococcus. J Am Geriatr Soc. 2004 Jan; 52(1):46-50.
Score: 0.002
-
Epstein-Barr virus DNA loads in adult human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis. 2003 Nov 01; 37(9):1244-9.
Score: 0.002
-
The dynamics of herpesvirus and polyomavirus reactivation and shedding in healthy adults: a 14-month longitudinal study. J Infect Dis. 2003 May 15; 187(10):1571-80.
Score: 0.002
-
Polyomavirus JCV excretion and genotype analysis in HIV-infected patients receiving highly active antiretroviral therapy. AIDS. 2003 Apr 11; 17(6):801-7.
Score: 0.002
-
Comparison of US inactivated split-virus and Russian live attenuated, cold-adapted trivalent influenza vaccines in Russian schoolchildren. J Infect Dis. 1996 Feb; 173(2):453-6.
Score: 0.001
-
Comparison of trivalent cold-adapted recombinant (CR) influenza virus vaccine with monovalent CR vaccines in healthy unselected adults. J Infect Dis. 1995 Jul; 172(1):253-7.
Score: 0.001
-
Effect of live attenuated, cold recombinant (CR) influenza virus vaccines on pulmonary function in healthy and asthmatic adults. Vaccine. 1990 Jun; 8(3):217-24.
Score: 0.001